Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

Study:

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

Rationale:

n/a

Purpose:

To determine the safety and efficacy of SNX-111 in controlling severe, chronic pain in cancer and AIDS patients.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
HIV Infections
Cancer
Pain		 Drug: Ziconotide Phase 2

Verified by Neurex March, 1998

Sponsored by: Neurex
Information provided by: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov identifier: NCT00002160

Study Type: Interventional

Study Design: Treatment, Double-Blind, Safety Study

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.